HealthEquity, Inc
HQY
$96.37
+3.19%
HealthEquity, Inc. is a leading provider of technology-enabled services that empower consumers to make healthcare saving and spending decisions, primarily through tax-advantaged Health Savings Accounts (HSAs) and other consumer-directed benefits like FSAs and HRAs. As the largest HSA custodian in the United States, HealthEquity differentiates itself through its integrated platform that combines payment processing, investment advice, and personalized benefit information, serving millions of accounts for employers and health plans. The current investor narrative centers on the company's robust growth trajectory, driven by rising HSA adoption, increasing interest rates on custodial cash, and successful cross-selling of its broader benefits portfolio, which has fueled strong revenue and earnings momentum. Recent quarterly results have exceeded expectations, with revenue growth accelerating and margins expanding, while the stock has rallied to near its 52-week high, reflecting optimism about the company's ability to sustain double-digit growth and capitalize on the secular shift toward consumer-directed healthcare.…
HQY
HealthEquity, Inc
$96.37
Related headlines
HQY 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HealthEquity, Inc's 12-month outlook, with a consensus price target around $118.53 and implied upside of +23.0% versus the current price.
Average Target
$118.53
0 analysts
Implied Upside
+23.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $135
Analyst target range
HealthEquity has coverage from 15 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.33 on a 1-5 scale, where 1 is Strong Buy). The average target price is $118.53, implying an upside of 12.4% from the current price of $105.41. The distribution is heavily bullish, with no sell ratings and only a few holds, reflecting strong conviction in the company's growth story. The target price range spans from a low of $105.00 to a high of $135.00, with the low target essentially at the current price, suggesting that even the most bearish analyst sees limited downside, while the high target implies a 28.1% upside, likely assuming continued strong HSA adoption and margin expansion. Recent institutional actions have been positive, with upgrades from BMO Capital (April 2026) and reaffirmations of Outperform/Buy ratings from RBC, Barrington, and Deutsche Bank, indicating a supportive sentiment trend. The relatively tight spread between the low and high targets (28.6% difference) suggests moderate uncertainty, but the overall bullish consensus and recent upgrades point to a favorable outlook.
Bulls vs Bears: HQY Investment Factors
HealthEquity presents a compelling growth story with accelerating revenue, strong margins, and a bullish analyst consensus, but the stock trades at a premium valuation that leaves little margin for error. The bull case is supported by a PEG ratio of 0.27 and a forward PE of 19.35x, suggesting the market expects substantial earnings growth, while the bear case hinges on the sustainability of revenue growth and the impact of potential rate cuts. The most critical tension is whether the company can maintain its growth trajectory and margin expansion to justify its premium multiple, or if a slowdown in HSA adoption or a decline in interest rates will compress the valuation. Currently, the evidence slightly favors the bulls given the strong fundamentals and analyst support, but the risk-reward is balanced.
Bullish
- Accelerating Revenue Growth: Q1 FY2027 revenue grew 7.19% YoY to $354.6M, accelerating from 3.8% growth in the prior quarter, demonstrating improving momentum in HSA adoption and custodial fee income.
- Strong Profitability and Margins: Operating margin is 24.6% and net margin is 16.4%, well above industry norms, reflecting efficient scaling and the high-margin nature of custodial services.
- Undervalued on PEG Ratio: With a PEG ratio of 0.27, the stock trades at a significant discount to its growth rate, suggesting the market is underpricing future earnings potential.
- Bullish Analyst Consensus: 15 analysts rate HQY a Strong Buy (mean 1.33), with an average target of $118.53, implying 12.4% upside from the current price of $105.41.
Bearish
- Premium Valuation vs Peers: Trailing PE of 34.27x is 55.8% above the industry average of 22x, leaving limited room for multiple expansion if growth disappoints.
- Revenue Growth Below Historical Levels: Q1 FY2027 growth of 7.19% is modest compared to the 18.2% increase over the past four quarters, indicating a slowdown from earlier double-digit rates.
- Dependence on Interest Rates: Financial services revenue, which benefits from high interest rates on HSA cash, could decline if the Fed cuts rates, pressuring earnings.
- High Short Interest: Short ratio of 5.32 suggests elevated bearish sentiment, which could lead to volatility if the stock misses expectations.
HQY Technical Analysis
HealthEquity's stock is in a clear sustained uptrend, with a 1-year price change of +15.76% and a 6-month change of +33.61%. The current price of $105.41 sits at 97.9% of its 52-week range (low of $72.76, high of $107.62), indicating the stock is trading near its highs, which typically signals strong momentum and investor confidence, though it also raises the risk of short-term overextension. The stock has outperformed the S&P 500 over the past 3 months (relative strength of +16.94%) and 6 months (+22.54%), but has underperformed over the past year (relative strength of -4.72%), suggesting the recent acceleration is a relatively new development.
Beta
0.23
0.23x market volatility
Max Drawdown
-30.6%
Largest decline past year
52-Week Range
$73-$108
Price range past year
Annual Return
+9.2%
Cumulative gain past year
| Period | HQY Return | S&P 500 |
|---|---|---|
| 1m | -7.5% | +5.5% |
| 3m | +9.5% | +1.7% |
| 6m | +26.0% | +12.2% |
| 1y | +9.2% | +18.6% |
| ytd | +5.8% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HQY Fundamental Analysis
HealthEquity's revenue trajectory is robust, with the most recent quarter (Q1 FY2027, ended April 30, 2026) posting revenue of $354.6 million, a 7.19% year-over-year increase. This growth is accelerating from the prior quarter's 3.8% YoY growth (Q4 FY2026 revenue of $334.6 million), and the company has consistently grown revenue from $299.9 million in Q2 FY2025 to $354.6 million now, a 18.2% increase over four quarters. Revenue is diversified across service fees ($122.9 million), financial services (including custodial fees, $174.3 million), and credit/debit card interchange ($57.4 million), with the financial services segment benefiting from higher interest rates on HSA cash balances.
Quarterly Revenue
$354641000.0B
2026-04
Revenue YoY Growth
+7.2%
YoY Comparison
Gross Margin
72.3%
Latest Quarter
Free Cash Flow
$487637000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HQY Overvalued?
Given HealthEquity's positive net income, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE stands at 34.27x, while the forward PE is 19.35x, implying the market expects significant earnings growth (a 43.5% reduction in PE). This gap is supported by the PEG ratio of 0.27, which suggests the stock is undervalued relative to its growth rate, and the consensus EPS estimate of $6.01 for the current fiscal year, which would represent a 633% increase from the trailing EPS of $0.82 (though this is skewed by one-time items). Compared to the industry average PE of 22x (from valuation data), HealthEquity trades at a 55.8% premium, but this premium is justified by its superior growth, as evidenced by its 24.6% operating margin and 16.4% net margin, which are well above industry norms. Historically, the stock's PE has ranged from a low of 25x (Q1 FY2027) to a high of 325x (Q3 FY2025), with the current trailing PE of 34x near the lower end of that range, suggesting the stock is not overvalued relative to its own history, especially considering the forward PE of 19x is near the historical low.
PE
34.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 25x~142x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.48, which is manageable but not negligible, and a reliance on interest income from custodial cash, which is sensitive to Fed rate decisions. The company's net margin of 16.4% is healthy, but a 100 basis point cut in rates could reduce financial services revenue, which constitutes a significant portion of total revenue. Additionally, the trailing PE of 34.27x implies high expectations; any earnings miss could trigger a sharp de-rating. Free cash flow is strong at $487.6M TTM, providing a cushion, but the company's growth is dependent on continued HSA adoption, which could slow if healthcare policy changes. Market risks include a premium valuation relative to peers (55.8% above industry average PE), which could compress if growth decelerates or if the market rotates away from growth stocks. The stock's beta of 0.233 suggests low market correlation, but it is still subject to sector-specific risks, such as regulatory changes to HSAs or increased competition from fintech entrants. The short ratio of 5.32 indicates potential for short squeezes but also reflects bearish sentiment that could amplify downside moves. In the worst-case scenario, a combination of slowing revenue growth, a rate cut cycle, and a market selloff could drive the stock down to its 52-week low of $72.76, representing a 31% decline from the current price of $105.41. This would likely occur if the company misses earnings estimates, guidance is lowered, and analysts downgrade the stock, leading to a de-rating from its current premium multiple.